Evidence map›Paper›PMID 38462489›Full record

Observational studyInternational journal for quality in health care : journal of the International Society for Quality in Health Care2024

How are we handling protein drugs in hospitals? A human factors and systems engineering approach to compare two hospitals and suggest a best practice.

Clàudia Sabaté-Martínez, Mattias Paulsson, Silvia González-Suárez, Ulla Elofsson, Anna Millqvist Fureby, Marie Wahlgren, Carmen López-Cabezas

Open access · hybridAbstract readObservational Study
In one paragraph

Observational study in International journal for quality in health care : journal of the International Society for Quality in Health Care, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
3.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Clàudia Sabaté-MartínezDepartment of Women's and Children's Health, Uppsala University, Akademiska sjukhuset, Entrance 95/96, Uppsala 751 85, Sweden.ORCID 0000-0002-8455-4435
Mattias PaulssonDepartment of Women's and Children's Health, Uppsala University, Akademiska sjukhuset, Entrance 95/96, Uppsala 751 85, Sweden.ORCID 0000-0002-2514-6618
Silvia González-SuárezPharmacy Service, Hospital Clínic Barcelona, c/Villarroel 170, 08036, Spain.
Ulla ElofssonRISE Research Institute of Sweden, AB, Box 857, 501 15, Borås, Stockholm 11428, Sweden.ORCID 0000-0002-3350-0242
Anna Millqvist FurebyRISE Research Institute of Sweden, AB, Box 857, 501 15, Borås, Stockholm 11428, Sweden.ORCID 0000-0001-9891-8968
Marie WahlgrenDepartment of Food Technology, Lund University, P.O. Box 124, Lund 22100, Sweden.ORCID 0000-0002-1705-3964
Carmen López-CabezasPharmacy Service, Hospital Clínic Barcelona, c/Villarroel 170, 08036, Spain.ORCID 0000-0003-3621-4433
Hospital Clínic de Barcelona · ESRISE Research Institutes of Sweden · SEUppsala University Hospital · SELund University · SE

Funding

Innovative Medicines Initiative RealHOPE grant n° 101007939Innovative Medicines Initiative RealHOPE grant number 101007939
6 · The paper itself

Abstract

Biopharmaceuticals are complex biological molecules that require careful storage and handling to ensure medication integrity. In this study, a work system analysis of real-world protein drug (PD) handling was performed with the following goals: identify main barriers and facilitators for successful adherence to accepted recommendations in PD handling, analyse differences in two organizations, and define a Best Current Practice in the real-life handling of PDs based on the results of the work system analysis. Observational study was held in two university hospitals in Spain and Sweden. Based on the Systems Engineering Initiative for Patient Safety (SEIPS) model, the tools chosen were: the PETT scan, in order to indicate the presence of barriers or facilitators for the PETT components (People, Environment, Tools, Tasks); the Tasks and tools matrices to construct a checklist to record direct observations during the real-life handling of biopharmaceuticals, and the Journey map to depict the work process. Observations were performed between March and November 2022. Each episode of direct observation included a single protein drug in some point of the supply chain and considered all the elements in the work system. Based on the results of the work system analysis and the literature review, the authors propose a list of items which could be assumed as Best Current Practice for PDs handling in hospitals. There were a total of 34 observations involving 19 PDs. Regarding People involved in the work process, there was a diversity of professionals with different previous training and knowledge, leading to an information gap. With respect to Environment, some structural and organizational differences between hospitals lead to risks related to the time exposure of PDs to room temperature and mechanical stress. Some differences also existed in the Tools and Tasks involved in the process, being especially relevant to the lack of compatibility information of PDs with new technologies, such as pneumatic tube system, robotic reconstitution, or closed-system transfer devices. Finally, 15 suggestions for best current practice are proposed. Main barriers found for compliance with accepted recommendations were related to the information gap detected in professionals involved in the handling of protein drugs, unmonitored temperature, and the lack of compatibility information of protein drugs with some new technologies. By applying a Human Factors and Systems Engineering Approach, the comparison of two European hospitals has led to a suggested list of Best Current Practices in the handling of protein drugs in a hospital.

Indexed as

Biological ProductsHospitalsThiazolesTriazolesHumansPatient SafetySpain2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazoleBiological ProductsThiazolesTriazoleschemical stabilityhospital pharmacyhuman factormonoclonal antibodiesprotein aggregationprotein handling

Identifiers

PMID38462489
PMCPMC11002458
OpenAlexW4392637063

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.